Impact of pneumatic tube transportation on the aggregation of monoclonal antibodies in clinical practice

被引:0
|
作者
Cohrs, Michaela [1 ]
Clottens, Nele [2 ]
Ramaut, Pieter [2 ]
Braeckmans, Kevin [1 ]
De Smedt, Stefaan [1 ]
Bauters, Tiene [2 ]
Svilenov, Hristo L. [1 ,3 ]
机构
[1] Univ Ghent, Lab Gen Biochem & Phys Pharm, Ottergemsesteenweg 460, B-9000 Ghent, Belgium
[2] Ghent Univ Hosp, Pharm Dept, Corneel Heymanslaan 10, B-9000 Ghent, Belgium
[3] Tech Univ Munich, TUM Sch Life Sci, Biopharmaceut Technol, Emil Erlenmeyer Forum 5, D-85354 Freising Weihenstephan, Germany
关键词
Antibody drugs; Biopharmaceutics; Mechanical stress; Pneumatic tube system; Protein aggregation; Subvisible particles; Visible particles; NANOPARTICLE TRACKING ANALYSIS; PROTEIN AGGREGATION; QUALITY ATTRIBUTES; IMMUNOGENICITY; STRESS; CAVITATION; PRODUCT; PARTICLES; STABILITY; AGITATION;
D O I
10.1016/j.ejps.2024.106952
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Postproduction handling and in-hospital transportation of antibody drugs cause mechanical stress, including interfacial and shear stress, that can induce antibody unfolding and aggregation. The handling practices differ significantly between hospitals and the impact on protein stability is unknown. For example, the mechanical stress caused by transport via pneumatic tube systems (PTS) on therapeutic antibody aggregation is a potential safety and quality gap. The aim of this study was to investigate whether mechanical stress and PTS transportation in a hospital cause aggregation of five commonly used antibody drugs diluted in infusion bags. Orthogonal analytical methods showed that the handling and PTS transportation in this hospital did not cause aggregation of the investigated mAbs. The absence of aggregation could be explained by the reduction of interfacial stress due to headspace removal from the infusion bags and a mechanical sensor indicated that there was also only a moderate amount of mechanical stress caused by transportation with this particular PTS. Although this case study focuses on five antibody drugs and the practices in one hospital, the work demonstrates how to evaluate whether other handling and transportation practices cause significant mechanical stress that could compromise the quality and safety of antibody drugs.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] VALIDATION OF A PNEUMATIC TUBE SYSTEM FOR TRANSPORTATION OF BLOOD COMPONENTS AND BLOOD TEST TUBES
    Quaglietta, A.
    Bonfini, T.
    Capone, A.
    Accorsi, P.
    Iacone, A.
    VOX SANGUINIS, 2010, 99 : 142 - 142
  • [32] MONOCLONAL-ANTIBODIES IN MEDICAL-PRACTICE
    ESTEVEZ, ME
    MEDICINA-BUENOS AIRES, 1986, 46 (04) : 468 - 471
  • [33] MONOCLONAL-ANTIBODIES IN CLINICAL MEDICINE
    KNAPP, W
    WIENER KLINISCHE WOCHENSCHRIFT, 1985, 97 (05) : 229 - 230
  • [34] MONOCLONAL AND POLYCLONAL ANTIBODIES - CLINICAL ASPECTS
    TAYLOR, RMR
    IMMUNOLOGY LETTERS, 1991, 29 (1-2) : 113 - 116
  • [35] MONOCLONAL-ANTIBODIES IN CLINICAL INVESTIGATIONS
    KUNG, PC
    CHANG, TW
    ZURAWSKI, VR
    CLINICAL BIOCHEMISTRY CONTEMPORARY THEORIES AND TECHNIQUES, 1984, 3 : 89 - 115
  • [36] THE CLINICAL USE OF MONOCLONAL-ANTIBODIES
    ENGLEMAN, EG
    WESTERN JOURNAL OF MEDICINE, 1983, 138 (05): : 707 - 707
  • [37] Therapeutic monoclonal antibodies in clinical neurology
    Buttmann, M.
    Wiendl, H.
    NERVENARZT, 2010, 81 (06): : 753 - 764
  • [38] MONOCLONAL-ANTIBODIES IN CLINICAL IMMUNOLOGY
    SEVIER, ED
    DAVID, GS
    MARTINIS, J
    DESMOND, WJ
    BARTHOLOMEW, RM
    WANG, R
    CLINICAL CHEMISTRY, 1981, 27 (11) : 1797 - 1806
  • [39] Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies
    Ron J. Keizer
    Alwin D. R. Huitema
    Jan H. M. Schellens
    Jos H. Beijnen
    Clinical Pharmacokinetics, 2010, 49 : 493 - 507
  • [40] Preclinical and clinical safety of monoclonal antibodies
    Tabrizi, Mohammad A.
    Roskos, Lohn K.
    DRUG DISCOVERY TODAY, 2007, 12 (13-14) : 540 - 547